Tempus AI (NASDAQ: TEM) has taken Wall Street by storm, ranking among the best-performing equities of 2025.
Notably, the precision medicine company, leveraging artificial intelligence (AI) to personalize patient treatments, has surged more than 80% year-to-date and is now trading at $62.
Interestingly, the rally has been fueled by enthusiasm from retail investors and Congress members. For instance, TEM remains one of the top-performing holdings in former House Speaker Nancy Pelosi’s portfolio.
But it might not be too late for those who missed the boat on TEM. The healthcare tech space still offers exciting opportunities. With that in mind, here are two tech-forward healthcare stocks worth considering:
Revvity (NYSE: RVTY)
Once part of PerkinElmer, Revvity (NYSE: RVTY) has quietly evolved into a tech-driven force in healthcare. The company has increased its focus on data, AI, and scientific software, and it’s starting to pay off.
To this end, Revvity is projecting earnings growth of 6.1% over the next five years as it positions itself as a leader in AI-enabled laboratory solutions.
Meanwhile, its flagship platforms, PKeye Workflow Monitor and Signals Research Suite, are helping laboratories operate more efficiently.
These cloud-based systems deliver real-time insights, automate workflows, and scale seamlessly. Notably, the Signals Software platform posted strong growth in 2024 and remains a key revenue driver heading into 2025.
From a stock performance standpoint, RVTY faced a challenging first half of 2025, with shares down 17% year-to-date. However, there’s been a recent rebound, with the share price gaining over 3% in the past week and is currently trading at $91.97.
BioNTech (NASDAQ: BNTX)
Best known for co-developing the COVID-19 vaccine with Pfizer, BioNTech (NASDAQ: BNTX)
aims to become a leader in cancer immunotherapy.
In the near term, momentum has picked up thanks to high-profile collaborations. Most recently, on June 2, BNTX stock surged 18% after announcing an $11.1 billion partnership with Bristol-Myers Squibb.
The deal focuses on developing BNT327, an experimental therapy targeting solid tumors. Thanks to this boost, BioNTech shares are up 14% over the past month, although they remain 6% lower year-to-date, trading at $108.
Despite short-term financial pressures, such as a wider Q1 net loss due to increased R&D spending, the company remains on solid footing with nearly €16 billion in cash reserves.
This financial strength gives BioNTech plenty of runway to advance its robust pipeline, which includes more than 25 clinical candidates across oncology and infectious diseases.
Featured image from Shutterstock
